28.6 C
United States of America
Tuesday, June 25, 2024

Aptose Pronounces Pricing of $8.4 Million Public Providing and a Concurrent $4 Million Non-public Placement with Hanmi Pharmaceutical Specific Occasions

Must read


SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Firm”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology firm creating extremely differentiated focused brokers to deal with hematologic malignancies, at the moment introduced the pricing of an underwritten public providing (the “Public Providing”) of 4,912,280 frequent shares of the Firm (the “Widespread Shares”) at a public providing worth of US $1.71 per share. Every Widespread Share can even embrace a warrant to buy a Widespread Share (a “Warrant Share”) at a worth of $1.71 per Warrant Share. Gross proceeds from the Public Providing, earlier than deducting underwriting reductions and commissions and providing bills payable by Aptose, are anticipated to be roughly US $8.4 million. The underwriters have been granted a 30-day choice to buy as much as an extra 736,842 Widespread Shares and/or 736,842 Warrants within the Public Providing, underneath the identical phrases and circumstances. 

Aptose additionally introduced the pricing of a concurrent $4 million personal placement (the “Non-public Placement”) of Widespread Shares with Hanmi Pharmaceutical, Inc. (“Hanmi”), Seoul, South Korea, representing possession of 19.97% of the excellent Widespread Shares of the Firm following the Non-public Placement. Below the phrases of the strategic funding, Hanmi will buy every Widespread Share at a worth of $1.90, representing an 11% premium over the value of the Widespread Shares issued within the Public Providing. The Firm can even concern Hanmi Warrants to buy Widespread Shares at a worth of $1.71 per Warrant Share. Upon the closing of the Non-public Placement, Hanmi could have happy its remaining funding obligations underneath the prevailing subscription settlement and investor rights settlement (introduced September 6, 2023) between Aptose and Hanmi.

The Public Providing is predicted to shut on or about January 30, 2024, topic to satisfaction of customary closing circumstances. The Non-public Placement is predicted to shut on or about January 31, 2024, topic to satisfaction of customary closing circumstances.

Aptose intends to make use of the online proceeds of the Public Providing and Non-public Placement to (i) help medical trials for tuspetinib; (ii) help manufacture of tuspetinib medical provides; and (iii) for working capital and basic company functions.

Newbridge Securities Company is performing as the only book-running supervisor for the Public Providing and as placement agent for the Non-public Placement.

No Widespread Shares, Pre-Funded Warrants or Warrants can be supplied or bought in Canada as a part of the Public Providing or Non-public Placement. The Public Providing and Non-public Placement are topic to the approval of the Toronto Inventory Trade (“TSX”) and Nasdaq. For the needs of TSX approval, the Firm is counting on the exemption set forth in Part 602.1 of the TSX Firm Guide, which supplies that the TSX won’t apply its requirements to sure transactions involving eligible interlisted issuers on a acknowledged trade, comparable to Nasdaq.

The securities to be bought within the Public Providing are being supplied by Aptose pursuant to a registration assertion on Type S-1 (File. No. 333-275870), together with a base prospectus, that was beforehand filed by Aptose with the Securities and Trade Fee (“SEC”) and was declared efficient on January 25, 2024. The Public Providing is being made solely via a written prospectus and prospectus complement that kind part of the registration assertion. Earlier than you make investments, it is best to learn the prospectus complement and the accompanying prospectus and different paperwork the Firm has filed with the SEC for extra full details about the Firm and the Public Providing. You might get these paperwork free of charge by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, copies of the ultimate prospectus complement could also be obtained, as soon as accessible, by contacting Newbridge Securities Company, Attn: Fairness Syndicate Division, 1200 North Federal Freeway, Suite 400, Boca Raton, FL 33432, by e-mail at [email protected] or by phone at (877) 447-9625. The securities to be bought to Hanmi haven’t been registered underneath the U.S. Securities Act of 1933, as amended, and can be issued in reliance on an exemption from the registration necessities thereof.

This press launch doesn’t represent a proposal to promote or the solicitation of affords to purchase any securities of Aptose, and shall not represent a proposal, solicitation or sale of any safety in any state or jurisdiction by which such provide, solicitation or sale could be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.

About Aptose

Aptose Biosciences is a clinical-stage biotechnology firm creating precision medicines addressing unmet medical wants in oncology, with an preliminary deal with hematology. The Firm’s small molecule most cancers therapeutics pipeline consists of merchandise designed to supply single agent efficacy and to boost the efficacy of different anti-cancer therapies and regimens with out overlapping toxicities. The Firm’s lead clinical-stage product, tuspetinib, is a as soon as every day oral remedy being studied as monotherapy and together remedy within the APTIVATE worldwide Part 1/2 growth trial in sufferers with relapsed or refractory acute myeloid leukemia (AML). For extra info, please go to www.aptose.com.

Ahead Wanting Statements

This press launch could include forward-looking statements inside the that means of Canadian and U.S. securities legal guidelines, together with, however not restricted to, statements regarding the therapeutic potential of tuspetinib, its medical growth and security profile, the anticipated use of proceeds from the Public Providing and the Non-public Placement, the anticipated time limits of the Public Providing and the Non-public Placement, the approval of the TSX and the Nasdaq and the timing thereof, in addition to statements regarding the Firm’s plans, goals, expectations and intentions and different statements together with phrases comparable to “proceed”, “anticipate”, “intend”, “will”, “ought to”, “would”, “could”, and different related expressions. Such statements mirror our present views with respect to future occasions and are topic to dangers and uncertainties and are essentially based mostly upon numerous estimates and assumptions that, whereas thought of cheap by us are inherently topic to vital enterprise, financial, aggressive, political and social uncertainties and contingencies. These dangers and uncertainties embrace, amongst others: the Firm’s means to fulfill the closing circumstances of the Public Providing or Non-public Placement, the timing or incidence of the closing, prevailing market circumstances, the anticipated use of the proceeds of the Public Providing or Non-public Placement which may change because of market circumstances or for different causes; and different dangers detailed from time-to-time in our ongoing quarterly filings, annual info types, annual stories and annual filings with Canadian securities regulators and the US Securities and Trade Fee.

Ought to a number of of those dangers or uncertainties materialize, or ought to the assumptions set out within the part entitled “Danger Elements” in our filings with Canadian securities regulators and the US Securities and Trade Fee underlying these forward-looking statements show incorrect, precise outcomes could fluctuate materially from these described herein. These forward-looking statements are made as of the date of this press launch and we don’t intend, and don’t assume any obligation, to replace these forward-looking statements, besides as required by legislation. We can’t guarantee you that such statements will show to be correct as precise outcomes and future occasions may differ materially from these anticipated in such statements. Buyers are cautioned that forward-looking statements usually are not ensures of future efficiency and accordingly traders are cautioned to not put undue reliance on forward-looking statements because of the inherent uncertainty therein.

For additional info, please contact:

aptose announces pricing of 8 4 million public offering and a concurrent 4 million private placement with hanmi pharmaceutical
CBJ Newsmakers


- Advertisement -spot_img

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -spot_img

Latest article